1. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 2012; 33: 1787–847.
2. McMachon E. Recent studies with eplerenone, a novel selective aldosterone receptor antagonist. Curr Opin Pharmacol 2001; 1: 190–6.
3. Weber KT, Villarreal D. Aldosterone, and antialdosterone therapy in congestive heart failure. Am J Cardiol 1993; 71 (Suppl. A): 3A–11A.
4. Yasky J, Ledesma GA, Tutera A, Collia LF. A fixed-dose combination of furosemide and spironolactone in digitalized congestive heart failure patients. Pharmatherapeutica 1986; 4 (8): 480–5.
5. Smith AG. Spironolactone in the long-term management of patients with congestive heart failure. Curr Med Res Opin 1980; 7 (2): 131–6.
6. Muller J. Spironolactone in the management of congestive heart failure: a rewiew. Clin Ther 1986; 9 (1): 63–76.
7. Arriza JL, Weinberger C, Cerelli G et al. Cloning of human mineralocorticoid receptor complementory DNA: structural and functional kinship with the glucocorticoid receptor. Sci 1987; 237 (4812): 268–75.
8. Корочкин И.М., Матвеева И.В. Гормональные нарушения и лечение больных с рефрактерными формами застойной сердечной недостаточности. Кардиология. 1977; 17 (8): 36–43.
9. Pierpont GL, Francis GS, Cohn JN. Effect of captopril on renal function in patients with congestive heart failure. Br Heart J 1981; 46 (5): 522–7.
10. Sharpe DN, Coxon RJ. Clinical and haemodynamic effects of low dose captopril in severe chronic heart failure. Br J Clin Phatmacol 1982; 14 (Suppl. 2): 161S–167S.
11. Nicholls MG, Espiner EA, Ikram H et al. Angiotensin II is more potent than potassium in regulating aldosterone in cardiac failure: evidence during captopril therapy. J Clin Endocrinol Metab 1981; 52 (6): 1253–6.
12. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990; 82 (5): 1730–6.
13. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;
316 (23): 1429–35.
14. Staessen J, Lijnen P, Fagard R et al. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981; 91 (3): 457–65.
15. Borghi C, Boschi S, Ambrosioni E et al. Evidence of a partial escape of reninangiotensine-aldosterone blocade in patients with acute myocardial infarctiontreated with ACE inhibitors. J Clin Pharmacol 1993; 33 (1): 40–5.
16. Lee AF, MacFadyen RJ, Struthers AD. Neurohormonal reactivationin heart failure patients on chronic ACE inhibitor therapy: a longitudinal study. Eur J Heart Fail 1999; 1 (4): 401–6.
17. Мареев В.Ю., Скворцов А.А., Челмакина С.М. и др. Способны ли ингибиторы АПФ эффективно контролировать активность ренин-ангиотензин-альдостероновой системы при длительном лечении хронической сердечной недостаточности? Кардиология. 1999; 39 (2): 27–34.
18. Urata H, Healy BH, Stewart R et al. Angiotensin II forming pathways in normal and failing human hearts. Circ Res 1990; 66 (4): 883–90.
19. Muller J. Regulation of aldosterone biosynthesis: physiological and clinical aspects. Monogr Endocrinol, 2nd ed NY.: Springer-Verlag, 1988.
20. MacFadyen RJ, Lee AF, Morton JJ et al. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 1999; 82 (1): 57–61.
21. Sato A, Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 2001; 29 (1): 13–21.
22. Мареев В.Ю., Скворцов А.А. Блокада эффектов альдостерона у больных сердечной недостаточностью: современный взгляд на проблему – эплеренон (ч. II). Сердечная недостаточность. 2011; 12 (4) [66]: 222–7.
23. Pitt B, Zannand F, Remme W et al. The effect of spirinilactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709–17.
24. Delyani J, Myles K, Funder J et al. Eplerenone (SC 66110), a highly selective aldosteron antagonist. Am J Hypertens 1998; 11: 94A.
25. Degasparo M, Joss U, Ramjoue et al. Three new epoxy-spironolactone derivates: characterization in vivo and in vitro. J Pharmacol Exp Ther 1987; 240: 650–6.
26. Cook CS, Berry LM, Kim DH et al. Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: differential metabolism by CYP3A4 and CYP3A5. Drug Metab Dispos 2002; 30 (12): 1344–51.
27. Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002; 15 (8): 709–16.
28. Sadee W, Dagcioglu M, Schroder R. Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans. J Pharmacol Exp Ther 1973; 185 (3): 686–95.
29. Pitt B, Roniker B. Eplerenone, a novel selective aldosteron receptor antagonist (SARA): dose – finding study in patients with heart failure. J Am Coll Cardiol 1999; 33: 188A–9A.
30. Zannad F, McMurray JJV, Drexler H et al. Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail 2010; 12 (6): 617–22.
31. Zannad F, McMurray JJV, Krum H et al. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. N Engl J Med 2011; 364: 11–21.
32. Swedberg K, Zannad F, McMurray JJ et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol 2012; 59 (18): 1598–603.
33. Pitt B, Remme W, Zannad F et al. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. N Engl J Med 2003; 348: 1309–21.
34. Mottram PM, Haluska B, Leano R et al. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 2004; 110 (5): 558–65.
35. Mak GJ, Ledwidge MT, Watson CJ et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J Am Coll Cardiol 2009; 54 (18): 1674–82.
36. Edwards NC, Ferro CJ, Kirkwood H et al. Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease. Am J Cardiol 2010; 106 (10): 1505–11.
37. Deswal A, Richardson P, Bozkurt B, Mann DL. Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). J Card Fail 2011; 17 (8): 634–42.
38. Edelmann FWR, Schmidt AG et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: The Aldo-DHF randomized controlled trial. JAMA 2013; 309 (8): 781–91.
39. Desai AS, Lewis EF, Li R et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J 2011; 162 (6): 966–72, e910.
40. Guichard J, Donald Clark II, Calhoun DA et al. Aldosterone receptor antagonists: current perspectives and therapies. Vasc Health Risk Manag 2013; 9: 321–31.
Авторы
Ю.Ф.Осмоловская, С.Н.Терещенко, И.В.Жиров
Отдел заболеваний миокарда и сердечной недостаточности ФГБУ РКНПК Минздрава РФ, Москва